Latest News about Thyrogen Global Supply

Genzyme Corporation is reporting that the global supply of Thyrogen will fluctuate through July 2011, causing temporary shortages in certain countries.

Genzyme anticipates a shortage in the United States beginning in mid-April and extending through mid-June and is notifying health care providers of the supply interruption so that they may schedule individual patient treatments appropriately during this time.

Communications about supplies in other countries are being managed by Genzyme affiliates at the regional level.

Regional disparities in supply are expected to continue to occur due to the logistical complexities of managing global demand with limited inventory.

Genzyme continues to work toward obtaining regulatory approvals worldwide for the fill/finish transfer to a third party contract manufacturing facility. All Thyrogen released from both Genzyme’s Allston, Massachusetts, plant and from the third party contract manufacturing facility has met all applicable quality standards and is safe for use in patients for whom it is indicated.

Genzyme also announced that it remains focused on restoring normal supply of Thyrogen globally as soon as possible.

For more information and articles about Thyrogen, which is given by injection to increase TSH prior to RAI testing or treatment for differentiated thyroid cancer (papillary, follicular, and their variants), visit